<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002326</url>
  </required_header>
  <id_info>
    <org_study_id>217B</org_study_id>
    <secondary_id>GS-93-204</secondary_id>
    <nct_id>NCT00002326</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients</brief_title>
  <official_title>A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of Combination Zidovudine (AZT) and 9-(2-Phosphonylmethoxyethyl)Adenine (PMEA; Adefovir) Treatment in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of combination&#xD;
      zidovudine (AZT) and PMEA (adefovir) therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive AZT daily and intravenous PMEA three times weekly for 4 weeks. An MTD will&#xD;
      be defined for this regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole&#xD;
             (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF on a stable regimen&#xD;
             for at least 4 weeks prior to study entry.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Mean CD4 count &lt;= 500 cells/mm3.&#xD;
&#xD;
          -  Been receiving AZT at 500 mg daily for at least 4 weeks prior to study entry.&#xD;
&#xD;
          -  Life expectancy of at least 3 months.&#xD;
&#xD;
        NOTE:&#xD;
&#xD;
          -  Kaposi's sarcoma is permitted provided patient has not received any systemic therapy&#xD;
             for KS within the past 4 weeks. Patients with a history of another malignancy must be&#xD;
             disease free for 6 months or more prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Inadequate venous access.&#xD;
&#xD;
          -  Active, serious infections (other than HIV infection) requiring parenteral antibiotic&#xD;
             therapy.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including symptoms of ischemia, congestive&#xD;
             heart failure, or clinically significant arrhythmia.&#xD;
&#xD;
          -  Active malignancy other than Kaposi's sarcoma.&#xD;
&#xD;
          -  Mental incapacity or illness that may affect compliance.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  ddI or ddC.&#xD;
&#xD;
          -  Interferon alpha.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Diuretics.&#xD;
&#xD;
          -  Investigational agents including d4T.&#xD;
&#xD;
          -  Chemotherapeutic agents.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Other nephrotoxic agents.&#xD;
&#xD;
          -  Immunomodulatory agents.&#xD;
&#xD;
          -  Parenteral therapy for an active, serious infection (other than HIV infection).&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 2 weeks prior to study entry:&#xD;
&#xD;
          -  ddI or ddC.&#xD;
&#xD;
          -  Interferon alpha.&#xD;
&#xD;
          -  Ganciclovir.&#xD;
&#xD;
          -  Foscarnet.&#xD;
&#xD;
          -  Diuretics.&#xD;
&#xD;
          -  Investigational agents including d4T.&#xD;
&#xD;
          -  Chemotherapeutic agents.&#xD;
&#xD;
          -  Amphotericin B.&#xD;
&#xD;
          -  Aminoglycoside antibiotics.&#xD;
&#xD;
          -  Other nephrotoxic agents.&#xD;
&#xD;
          -  Immunomodulatory agents.&#xD;
&#xD;
        Excluded within 4 weeks prior to study entry:&#xD;
&#xD;
        Systemic therapy for Kaposi's sarcoma.&#xD;
&#xD;
        Required:&#xD;
&#xD;
          -  AZT at a stable dose for at least 4 weeks prior to study entry. Current use of illicit&#xD;
             drugs (e.g., heroin or cocaine). Ingestion of substantial alcohol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Natl Cancer Institute</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Adenine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

